Selinexor for advanced hematologic malignancies.

abstract：:Non-Hodgkin lymphoma (NHL) is one of the most common cancers in childhood. The development of chemoresistance in tumor cells is one of the principal causes of treatment failure. This resistance has been associated with different mechanisms, one being the overexpression of anti-apoptotic proteins such as Bcl-xL. It has...

journal_title：Leukemia & lymphoma

authors： Hernandez-Luna MA,Rocha-Zavaleta L,Vega MI,Huerta-Yepez S

更新日期：2013-05-01 00:00:00

abstract：:One hundred and seventy-five hemato-oncologists and nuclear medicine specialists from 23 countries joined the 2-day 4th International Workshop on Positron Emission Tomography in Lymphoma held in October 2012. The meeting was under the auspices of the European Lymphoma Institute, the Lymphoma Study Association (LYSA) a...

journal_title：Leukemia & lymphoma

authors： Meignan M,Barrington S,Itti E,Gallamini A,Haioun C,Polliack A

更新日期：2014-01-01 00:00:00

abstract：:Pixantrone is a potentially more effective, less cardiotoxic alternative to doxorubicin for patients with aggressive non-Hodgkin lymphoma (aNHL). This phase I/II non-comparative study evaluated pixantrone in place of doxorubicin in the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone),...

journal_title：Leukemia & lymphoma

authors： Borchmann P,Herbrecht R,Wilhelm M,Morschhauser F,Hess G,Cernohous P,Veals SA,Singer JW,Engert A

更新日期：2011-04-01 00:00:00

abstract：:The association of myeloproliferative and lymphoproliferative disorders is well known after cytotoxic drug or radiation exposure, while it is remarkably rare prior to therapy. We report on a patient simultaneously diagnosed as having polycythemia vera and II3A follicle center cell non-Hodgkin lymphoma (grade 1). At th...

journal_title：Leukemia & lymphoma

authors： Rizzi R,Liso A,Pannunzio A,Carluccio P,Specchia G,Liso V

更新日期：2002-11-01 00:00:00

abstract：:An unusual case of aplastic anemia presenting in association with lymphoplasmacytic lymphoma and paroxysmal nocturnal hemoglobinuria is discussed. An insult to the hematological stem cell compartment may result in multiple pathological entities, potentially influencing our approach to the treatment of hematological cl...

journal_title：Leukemia & lymphoma

authors： Veidt RG,Ansari-Lari A,Brodsky RA

更新日期：2005-08-01 00:00:00

abstract：:Recently, lenalidomide and low dose dexamethasone were found to result in superior overall survival compared to lenalidomide and high dose dexamethasone. The immune suppressive effects of dexamethasone can antagonize lenalidomide immunomodulatory activity and may explain this observation. We conducted a retrospective ...

journal_title：Leukemia & lymphoma

authors： Baz R,Patel M,Finley-Oliver E,Lebovic D,Hussein MA,Miller KC,Wood M,Sher T,Lee K,Chanan-Khan AA

更新日期：2010-06-01 00:00:00

abstract：:Pulmonary marginal zone lymphoma is a rare disease arising from bronchial-associated lymphoid tissue (BALT). There is limited information on clinical presentation, natural history and treatment of this type of lymphoma. We conducted a retrospective review of patients with biopsy-proven BALT lymphoma treated at our ins...

journal_title：Leukemia & lymphoma

authors： Stefanovic A,Morgensztern D,Fong T,Lossos IS

更新日期：2008-07-01 00:00:00

abstract：:Immunomodulatory drugs (IMiDs) may favor autoimmune disease (AD) occurrence. We conducted a retrospective study to evaluate AD occurrence among IMiD-treated patients with myeloma. Patients were grouped into three classes depending on the type of IMiD engaged. The first group included patients treated with thalidomide ...

journal_title：Leukemia & lymphoma

authors： Montefusco V,Galli M,Spina F,Stefanoni P,Mussetti A,Perrone G,De Philippis C,Dalto S,Maura F,Bonini C,Rezzonico F,Pennisi M,Roncari L,Soldarini M,Dodero A,Farina L,Cocito F,Caprioli C,Corradini P

更新日期：2014-09-01 00:00:00

abstract：:The diagnosis of non-Hodgkin lymphoma (NHL) is increasingly common among the elderly and it is well recognized that this patient population may benefit from therapy. No guidelines exist for chemotherapy dosing in the elderly population, and a clear assessment of treatment toxicity and benefits has not been previously ...

journal_title：Leukemia & lymphoma

authors： Huntington SF,Talbott MS,Greer JP,Morgan DS,Reddy N

更新日期：2012-08-01 00:00:00

abstract：:The quinazoline antifolate N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N- methylamino]-2-thenoyl)-L-glutamic acid (ZD1694; Tomudex) is a potent inhibitor of thymidylate synthase and causes cell death through disruption of DNA synthesis and repair by blocking the obligatory thymidine nucleotide synthesis....

journal_title：Leukemia & lymphoma

authors： Ek O,Reaman GH,Crankshaw DL,Chelstrom LM,Myers DE,Uckun FM

更新日期：1998-02-01 00:00:00

abstract：:Preclinical studies suggest that bortezomib, through inhibition of nuclear factor-κB (NF-κB) activation, may enhance the effects of radioimmunotherapy. This phase I trial was designed to determine the maximum tolerated dose (MTD) of weekly bortezomib induction combined with Y-90-ibritumomab tiuxetan followed at the ti...

journal_title：Leukemia & lymphoma

authors： Roy R,Evens AM,Patton D,Gallot L,Larson A,Rademaker A,Cilley J,Spies S,Variakojis D,Gordon LI,Winter JN

更新日期：2013-03-01 00:00:00

abstract：:Multiple myeloma is a genetically heterogenous disease with a wide variety of characterized genetic aberrations. Until recently, the impact of these aberrations on patient outcome was not known. However, in the last 5-10 years, several genetic markers have been linked to patient outcome. One of the strongest predictor...

journal_title：Leukemia & lymphoma

authors： Keats JJ,Reiman T,Belch AR,Pilarski LM

更新日期：2006-11-01 00:00:00

abstract：:Systemic mast cell disease (SMCD) has a highly variable clinical expression and course. That SMCD is associated with hematologic disorders has been widely described. We report an unusual case of systemic mast cell disease and concurrent chronic myelomonocytic leukemia in a 60 year old male. ...

journal_title：Leukemia & lymphoma

authors： Smith JD,Lazarchick J

更新日期：1999-01-01 00:00:00

abstract：:Central to discovering novel approaches to treating leukemias and lymphomas is a clear understanding of the signaling networks which lead to unchecked cell cycle progression, proliferation, and survival. Cyclic-adenosine monophosphate (cAMP) responsive element-binding protein (CREB) represents a critical integrator of...

journal_title：Leukemia & lymphoma

authors： Mitton B,Cho EC,Aldana-Masangkay GI,Sakamoto KM

更新日期：2011-11-01 00:00:00

abstract：:High-dose therapy (HDT) is now recommended for patients under 60 years of age with chemosensitive relapsed aggressive non-Hodgkin's lymphoma. However, approximately half of these patients will be cured by HDT. Prognostic factors are needed to predict which patients with chemosensitive lymphoma to second-line therapy c...

journal_title：Leukemia & lymphoma

authors： Jabbour E,Peslin N,Arnaud P,Ferme C,Carde P,Vantelon JM,Bocaccio C,Bourhis JH,Koscielny S,Ribrag V

更新日期：2005-06-01 00:00:00

abstract：:We have recently shown that antibodies to transcobalamin II (TCII) inhibit the in vitro growth of human and murine leukemic cells. This antiproliferative strategy targets the uptake of cobalamin (Cbl), an essential cofactor for two biochemical reactions in humans. To date there has been no appropriate cell culture mod...

journal_title：Leukemia & lymphoma

authors： McLean GR,Williams MJ,Woodhouse CS,Ziltener HJ

更新日期：1998-06-01 00:00:00

abstract：:Graft-versus-host disease (GVHD) represents the major barrier to successful allogeneic bone marrow transplantation. Positive and negative selection studies have unequivocally demonstrated that donor T cells are responsible for the induction phase of GVHD. Inhibition of the early steps of T cell antigen recognition lea...

journal_title：Leukemia & lymphoma

authors： Schlegel PG,Chao NJ

更新日期：1996-09-01 00:00:00

abstract：:Multiple myeloma (MM) is the top indication for high-dose chemotherapy (HDC) with autologous stem cell transplantation (SCT), a strategy which improves progression-free survival and potentially overall survival (OS). Novel induction regimens incorporating the immunomodulatory (IMID) agents, such as thalidomide and len...

journal_title：Leukemia & lymphoma

authors： Benson DM Jr,Panzner K,Hamadani M,Hofmeister CC,Bakan CE,Smith MK,Elder P,Krugh D,O'Donnell L,Devine SM

更新日期：2010-02-01 00:00:00

abstract：:The expression of c-kit receptor (c-kit R; CD117) and CD34 was examined in acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), chronic myeloid leukemia (CML) in blastic transformation (BT), and myelofibrosis (MF) in myeloid BT. In myeloid leukemia including AML, CML-myeloid BT and MF-myeloid BT, both c-kit R ...

journal_title：Leukemia & lymphoma

authors： Muroi K,Nakamura M,Amemiya Y,Suda T,Miura Y

更新日期：1995-01-01 00:00:00

abstract：:Ibrutinib and idelalisib are kinase inhibitors that have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Capable of inducing durable remissions, these agents also modulate the immune system. Both ibrutinib and idelalisib abrogate the tumor-supporting microenvironment by disrupting cell-cell interac...

journal_title：Leukemia & lymphoma

authors： Pleyer C,Wiestner A,Sun C

更新日期：2018-12-01 00:00:00

abstract：:Autologous stem cell transplantation (ASCT), intensifying anti-leukemic effects without significant treatment-related mortality (TRM), is particularly appealing in AML with favorable genetic/molecular profile. This study retrospectively evaluated the outcomes of post-remission treatment in consecutive favorable-risk A...

journal_title：Leukemia & lymphoma

authors： Beyar-Katz O,Lavi N,Ringelstein-Harlev S,Henig I,Yehudai-Ofir D,Haddad N,Fineman R,Ofran Y,Nov Y,Sahar D,Moustafa-Hawash N,Rowe JM,Zuckerman T

更新日期：2019-10-01 00:00:00

abstract：:Leukemia is a result of accumulating genetic alterations. The collaboration of mutations that offer survival and proliferative signals, together with mutations that result in lack of differentiation, is thought to cause a leukemic phenotype. The cyclic-AMP Response Element Binding Protein (CREB) is a transcription fac...

journal_title：Leukemia & lymphoma

authors： Shankar DB,Sakamoto KM

更新日期：2004-02-01 00:00:00

abstract：:Peripheral lymphopenia is a well-known negative prognostic marker in classical Hodgkin lymphoma (cHL). We characterized the peripheral B-cell compartment in a prospective cohort of 83 pediatric cHL patients. We observed significantly low total B-cell counts (<100 cells/µl) in 31 of 83 patients (37%). More specifically...

journal_title：Leukemia & lymphoma

authors： Hamdi L,Creidy R,Boudjemaa S,Hendel-Chavez H,Hugues P,Taoufik Y,Leblanc T,Coulomb A,Krzysiek R,Landman-Parker J,Besson C

更新日期：2020-10-23 00:00:00

abstract：:We conducted a population-based study to assess how positron emission tomography (PET) is currently used in patients with Hodgkin lymphoma (HL). Four cancer registries from northern Italy were used to identify patients with HL diagnosed from 2006 to 2008. Computed tomography (CT) and PET scans were collected before tr...

journal_title：Leukemia & lymphoma

authors： Luminari S,Cesaretti M,Tomasello C,Guida A,Bagni B,Merli F,Postiglione R,Mangone L,Versari A,Re F,De Lisi V,Ruffini L,Ferretti S,Cuneo A,Federico M

更新日期：2011-09-01 00:00:00

abstract：:Ponatinib is a pan-tyrosine kinase inhibitor (TKI) with efficacy in multirefractory CML patients who have failed other TKIs. Despite excellent response rates, resistance or intolerance may develop. We conducted a retrospective review of the outcome of patients with chronic (CP) and accelerated (AP) phase CML refractor...

journal_title：Leukemia & lymphoma

authors： Boddu P,Shah AR,Borthakur G,Verstovsek S,Garcia-Manero G,Daver N,Kadia T,Ravandi F,Jain N,Alhuraiji A,Burger J,Kornblau S,Pierce S,Dellasala S,Jabbour E,Kantarjian H,Cortes J

更新日期：2018-06-01 00:00:00

abstract：:Forty patients, with mainly poor risk haematological malignancies, were given the new regimen FLAG, comprising fludarabine, arabinosyl cytosine and G-CSF. Twenty four patients had acute myeloid leukaemia (AML), 8 patients myelodysplastic syndrome (MDS) and a further 8 patients had a variety of other haematological mal...

journal_title：Leukemia & lymphoma

authors： Nokes TJ,Johnson S,Harvey D,Goldstone AH

更新日期：1997-09-01 00:00:00

abstract：:Gene array studies on follicular lymphoma (FL) have associated non-malignant tumor-infiltrating immune cells with patient survival. We examined the role of such cells detectable by immunohistochemistry in a tissue microarray, focusing on plasmacytoid dendritic cells (pDCs). These cells physiologically produce interfer...

journal_title：Leukemia & lymphoma

authors： Butsch R,Lukas Waelti S,Schaerer S,Braun J,Korol D,Probst-Hensch N,Moch H,Kurrer M

更新日期：2011-07-01 00:00:00

abstract：:The relationship between histopathologic characteristics and treatment outcomes in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-based immunochemotherapy needs re-evaluation. Patients with newly diagnosed DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednis...

journal_title：Leukemia & lymphoma

authors： Hong J,Park S,Park J,Kim HS,Kim KH,Ahn JY,Rim MY,Jung M,Sym SJ,Cho EK,Shin DB,Lee JH

更新日期：2011-10-01 00:00:00

abstract：:Tumor necrosis factor alpha (TNF-alpha) and lymphotoxin alpha (LT-alpha) have been shown to play an important role in the pathogenesis of limphoproliferative disease. Both cytokines regulate cell-survival and cell-death in leukemic cells. TNF-alpha and LT-alpha are highly produced in chronic lymphotic leukemia (CLL) a...

journal_title：Leukemia & lymphoma

authors： Jevtovic-Stoimenov T,Kocic G,Pavlovic D,Macukanovic-Golubovic L,Marjanovic G,Djordjevic V,Tosić N,Pavlović S

更新日期：2008-11-01 00:00:00

abstract：:This study aimed to analyze the frequency of peripheral Mo-myeloid-derived suppressor cells (Mo-MDSCs) in newly diagnosed CLL patients and to correlate their level with other prognostic factors such as frequency of CD38 cells and ZAP-70 cells and with the clinical response and survival outcomes in these patients. Fift...

journal_title：Leukemia & lymphoma

authors： Zahran AM,Moeen SM,Thabet AF,Rayan A,Abdel-Rahim MH,Mohamed WMY,Hetta HF

更新日期：2020-07-01 00:00:00